Cleerly
Surgeries & Interventions November 19, 2026
Left atrial appendage occlusion (LAAO) has become one of cardiology’s most contentious therapies. Now, a new JACC evidence review argues that the answer comes from looking at patients as individuals rather than study populations.
Cardiology Pharmaceuticals November 16, 2026
We’ve known for months now that neither Novo’s ZEUS trial nor Novartis’ Lp(a)HORIZON yielded positive topline results for their respective drugs and while the full data at AHA 2026 wasn’t a win for these pharma giants, it’s certain to help shape cardiac science.
Cardiology Pharmaceuticals November 12, 2026
Adding anticoagulants to antiplatelet therapy after stroke has always meant trading clots for bleeds, but that’s changing thanks to Bayer’s asundexian (Sunharbo), which just became the first-ever FDA-approved Factor XIa inhibitor for secondary stroke prevention.